Cargando…

COVID-19 vaccine platforms: Delivering on a promise?

The emergence of the novel SARS-CoV-2 and COVID-19 has brought into sharp focus the need for a vaccine to prevent this disease. Vaccines have saved millions of lives since their introduction to the public over 200 years ago. The potential for vaccination reached new heights in the mid-20th century w...

Descripción completa

Detalles Bibliográficos
Autores principales: Verdecia, Mark, Kokai-Kun, John F., Kibbey, Maura, Acharya, Sarita, Venema, Jaap, Atouf, Fouad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381795/
https://www.ncbi.nlm.nih.gov/pubmed/34033528
http://dx.doi.org/10.1080/21645515.2021.1911204
_version_ 1783741434195607552
author Verdecia, Mark
Kokai-Kun, John F.
Kibbey, Maura
Acharya, Sarita
Venema, Jaap
Atouf, Fouad
author_facet Verdecia, Mark
Kokai-Kun, John F.
Kibbey, Maura
Acharya, Sarita
Venema, Jaap
Atouf, Fouad
author_sort Verdecia, Mark
collection PubMed
description The emergence of the novel SARS-CoV-2 and COVID-19 has brought into sharp focus the need for a vaccine to prevent this disease. Vaccines have saved millions of lives since their introduction to the public over 200 years ago. The potential for vaccination reached new heights in the mid-20th century with the development of technologies that expanded the ability to create novel vaccines. Since then, there has been continued technological advancement in vaccine development. The resulting platforms provide the promise for solutions for many infectious diseases, including those that have been with us for decades as well as those just now emerging. Each vaccine platform represents a different technology with a unique set of advantages and challenges, especially when considering manufacturing. Therefore, it is essential to understand each platform as a separate product and process with its specific quality considerations. This review outlines the relevant platforms for developing a vaccine for SARS-CoV-2 and discusses the advantages and disadvantages of each.
format Online
Article
Text
id pubmed-8381795
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-83817952021-08-24 COVID-19 vaccine platforms: Delivering on a promise? Verdecia, Mark Kokai-Kun, John F. Kibbey, Maura Acharya, Sarita Venema, Jaap Atouf, Fouad Hum Vaccin Immunother Review The emergence of the novel SARS-CoV-2 and COVID-19 has brought into sharp focus the need for a vaccine to prevent this disease. Vaccines have saved millions of lives since their introduction to the public over 200 years ago. The potential for vaccination reached new heights in the mid-20th century with the development of technologies that expanded the ability to create novel vaccines. Since then, there has been continued technological advancement in vaccine development. The resulting platforms provide the promise for solutions for many infectious diseases, including those that have been with us for decades as well as those just now emerging. Each vaccine platform represents a different technology with a unique set of advantages and challenges, especially when considering manufacturing. Therefore, it is essential to understand each platform as a separate product and process with its specific quality considerations. This review outlines the relevant platforms for developing a vaccine for SARS-CoV-2 and discusses the advantages and disadvantages of each. Taylor & Francis 2021-05-25 /pmc/articles/PMC8381795/ /pubmed/34033528 http://dx.doi.org/10.1080/21645515.2021.1911204 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Review
Verdecia, Mark
Kokai-Kun, John F.
Kibbey, Maura
Acharya, Sarita
Venema, Jaap
Atouf, Fouad
COVID-19 vaccine platforms: Delivering on a promise?
title COVID-19 vaccine platforms: Delivering on a promise?
title_full COVID-19 vaccine platforms: Delivering on a promise?
title_fullStr COVID-19 vaccine platforms: Delivering on a promise?
title_full_unstemmed COVID-19 vaccine platforms: Delivering on a promise?
title_short COVID-19 vaccine platforms: Delivering on a promise?
title_sort covid-19 vaccine platforms: delivering on a promise?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381795/
https://www.ncbi.nlm.nih.gov/pubmed/34033528
http://dx.doi.org/10.1080/21645515.2021.1911204
work_keys_str_mv AT verdeciamark covid19vaccineplatformsdeliveringonapromise
AT kokaikunjohnf covid19vaccineplatformsdeliveringonapromise
AT kibbeymaura covid19vaccineplatformsdeliveringonapromise
AT acharyasarita covid19vaccineplatformsdeliveringonapromise
AT venemajaap covid19vaccineplatformsdeliveringonapromise
AT atouffouad covid19vaccineplatformsdeliveringonapromise